A Tecfidera Comeback? Investors Await More On Patent Plans From Biogen
Biogen has been granted new US patents for Tecfidera after generics already launched. It's unclear how Biogen will proceed but management could shed more light on the matter during the first quarter call.
You may also be interested in...
In this week's podcast version of Five Must-Know Things, hear about possible new life for Tecfidera, activist investors and GSK, a new mRNA vaccine in Europe, diversity in clinical trials, and a look at last year’s drug launches.
Biogen feels a decision on its appeal over Tecfidera is due any day now, but management was cautious over the potential to scrub the market of generics following market formation last year.
The company has identified 600 sites of care to treat Alzheimer's patients with aducanumab in the US and is confident on its pricing strategy, management said.